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Abstract:  The  last  two  decades  have  seen  remarkable  progress  and  improvements  in 
optical  biosensor  systems  such  that  those  are  currently  seen  as  an  important  and  
value-adding component of modern drug screening activities. In particular the introduction 
of microplate-based biosensor systems holds the promise to match the required throughput 
without  compromising  on  data  quality  thus  representing  a  sought-after  complement  to 
traditional fluidic systems. This article aims to highlight the application of the two most 
prominent optical biosensor technologies, namely surface plasmon resonance (SPR) and 
optical waveguide grating (OWG), in small-molecule screening and will present, review 
and discuss the advantages and disadvantages of different assay formats on these platforms. 
A particular focus will be on the specific advantages of the inhibition in solution assay 
(ISA) format in contrast to traditional direct binding assays (DBA). Furthermore we will 
discuss different application areas for both fluidic as well as plate-based biosensor systems 
by considering the individual strength of the platforms. 
Keywords:  screening;  fragment;  ligand;  biosensor;  surface  plasmon  resonance;  optical 
waveguide grating; drug discovery  
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Abbreviations 
DBA    direct binding assay 
FBDD   fragment-based drug discovery 
HTS    high throughput screening 
ISA    inhibition in solution assay 
NMR    nuclear magnetic resonance 
OWG    optical waveguide grating 
SCA    surface competition assay 
SPR    surface plasmon resonance 
TDC    target definition compound  
1. Introduction 
Label-free optical detection systems for drug discovery and in particular for small-molecule drug 
screening have gained popularity during the past decade within industry and academia [1]. This is on 
one  hand  a  direct  consequence  of  the  continuous  development  of  novel  and  enhanced  label-free 
detection  systems  showing  improved  assay  robustness  and  better  detection  limits  combined  with 
increased throughput and multiplexing that matches the proliferating needs. On the other hand this is 
also a reflection of the increased demand of modern drug discovery to provide detailed biophysical 
ligand binding data like kinetic and thermodynamic information in addition to the more typical binding 
and/or affinity data [2–4]. Altogether this has positioned surface plasmon resonance (SPR) technology 
as a prominent approach to deliver orthogonal ligand binding information into the selection process 
e.g., during hit evaluation after a high-throughput (HTS) screen [5]. The adoption of SPR technology 
was further accelerated by increasing demand  in efficient fragment-based  drug discovery (FBDD) 
approaches [6,7]; this has made SPR technology a validated tool to detect small-molecule interactions. 
The recent success of SPR technology has increased the interest and demand within big pharma 
industry  for  complementary  platforms  and  technologies  that  could  handle  samples  in  a  parallel 
high(er)-throughput  fashion.  Besides  other  alternative  optical  detection  systems,  the  use  of  planar 
waveguide systems  using microplates  is  seen as  an interesting complement to  SPR systems, as it 
enables small-molecule screening with increased throughput without compromising on data quality. 
Those optical waveguide grating (OWG) systems are either making use of resonant waveguide grating 
(Corning  EPIC  system)  [8]  or  nanostructured  optical  grating  (also  known  as  photonic  crystals  as 
employed in the SRU BIND system) [9]. They have in common that they, in analogy to SPR-based 
approaches, are typically used to detect the binding of compounds to immobilised target proteins that 
are attached to a modified biosensor surface. The ability to attach even entire cells onto the biosensor 
surface and to follow the cellular responses upon challenge with a compound in real-time [10], opens 
up  for  novel  and  interesting  screening  approaches.  However,  this  article  will  solely  focus  on 
biochemical assays and the challenges that are associated with those.  
One of the main challenges in either using SPR- or OWG-based approaches relate to the used target 
protein. As already mentioned, a common approach is the tethering of the target protein onto the 
biosensor surface using a range of coupling chemistries and immobilisation strategies [11]. A key Sensors 2012, 12  4313 
 
 
success factor for establishing a system that can be used for screening of larger compound libraries 
(i.e., screening hundreds of compounds/day) is linked to the successful manipulation of the inherent 
instability of most target protein constructs, i.e., the decrease in ligand-binding competence over time. 
This is particular important for microfluidic systems like the typical SPR-based Biacore instrument, as 
the screened compounds are frequently tested against the same sensor surface which needs to remain 
relatively constant in ligand binding activity during the entire series of experiments. There have been 
some intelligent approaches developed that either help to minimize or to compensate for the loss of 
ligand-binding activity during the course of a SPR screening campaign [7]. However, important drug 
targets like GPCRs, that frequently show a high intrinsic instability once extracted from the membrane, 
are frequently resilient to such approaches. Only dedicated efforts aiming to generate stabilised versions 
of some selected and well-behaving GPCRs (designated as stabilized receptors or STARs) enabled 
recently the successful screening against two important GPCR targets using SPR methodology [12,13]. 
This highlights the importance of having access to stable protein reagents. As OWG-based approaches 
are typically performed using plate-based systems, this becomes much less of an issue as the modified 
sensor surface is only used in a single binding experiment and typically gets disposed after its usage. 
This  comes  at  the  cost  of  an  amplified  target  protein  consumption  that  can  be  in  the  range  of  
several orders of magnitude higher as compared to a fluidic SPR-based system and might exclude 
OWG-approaches for screening campaigns that have limited access to larger amounts of target protein. 
A subsequent  challenge  relates to the reliability of detecting  genuine  binders during a screening 
campaign. This is very much dictated by the attainable sensitivity of the system as well as the ability to 
discriminate specific from unspecific binding events and is reflected in the rate of false negative and false 
positive hits respectively. The physical behaviour of compounds or fragments in aqueous solutions is 
quite frequently leading to situations where one can observe apparently specific binding events at lower 
compound concentration with a more dominant unspecific binding component at elevated compound 
concentrations. Usually one defines in advance a maximum binding signal that is expected for a 1:1 
binding and uses that information to exclude compounds with unrealistically high stoichiometry [7]. 
Another  common  approach  is  to  screen  against  a  modified  target  protein,  either  by  a  site  directed 
mutation  or  chemically  modified,  in  the  targeted  binding  site  [5].  Thus  performing  concentration-
response experiments will usually help to understand the mode of activity of such compounds better and 
help to remove aggregation-based compounds from the initial list of hits [14]. In contrast to that it is 
much more challenging to deal with false negative hits as this is very much determined by the sensitivity 
of  the  system.  Here  one  needs  to  distinguish  between  the  mass  sensitivity  that  represents  the 
characteristics of the sensor structure itself and is thus technology- and instrument specific, and the assay 
sensitivity that is additionally influenced by other factors such as the molecular weight of the interacting 
partners, their affinity as well as total concentration and density in the buffer and on the biosensor 
respectively. Simulations displaying the minimum required ratio between the total ligand concentration 
and the affinity as a function of the molecular weight of the ligand as well as the protein show, that assay 
sensitivity is lower with increasing molecular weight of the protein and decreasing molecular weight of 
the ligand [15]. This creates particular issues for studying low-affinity small-molecule fragment binding 
to larger protein systems, in particular if those are not displaying good ligand binding competence after 
the  immobilisation  to  the  biosensor.  Thus  different  assay  formats  have  been  developed  that  can 
specifically address the issue of low assay sensitivity in particular for small-molecule work. Sensors 2012, 12  4314 
 
 
The direct binding assay (DBA) is widely used in kinetic analysis as well as screening studies [16,17].  
It has the essential  feature that compounds (the  analyte) interact directly  with the  binding site of 
immobilised target proteins on the cost of low assay sensitivity as described earlier. By introducing a 
second analyte molecule that binds specifically to the same binding site and exhibits increased assay 
sensitivity due to its enhanced molecular weight; it will compete for the same binding site with the first 
analyte and thus serve as a well-observable reporter molecule for the binding of the first analyte [18,19].  
As both analytes compete for the same binding site at the sensor surface this assay is also called 
surface competition assay (SCA). However, no binding reaction is taking place in solution. This is 
contrasted by the inhibition in solution assay (ISA) with the fundamental difference that binding of the 
analyte to the target protein is occuring free in solution [20,21]. The second analyte or an analogue 
thereof (often referred to as target definition compound or TDC) is tethered onto the biosensor surface 
and serves as a tool to determine the change in the free target protein concentration in the presence of 
the first analyte. This assay format was used particular in the early days of SPR more frequently as the 
mass  sensitivity  of  those  first  instruments  was  not  suitable  to  reliably  quantitate  small  molecule 
binding to macromolecular targets. The enhancements in mass sensitivity seen particular during the 
last decade in the field of SPR has allowed studying those interactions directly. However, with the 
elevated FBDD efforts and thus fragment screening demand this assay format has clearly an enabling 
potential and has been already applied successfully in this context [22].  
Figure 1. Assay formats. In the direct binding assay the target is immobilized directly on 
the biosensor. In brackets, a variant of the DBA, the so called surface competition assay 
(SCA) is shown. Both compounds compete for the same binding site at the sensor surface. 
In the inhibition in solution assay (ISA), binding of the analyte or compound to the target 
protein  is  occurring  free  in  solution.  In  the  ISA  the  order  of  addition  of  protein  and 
competing small molecule can vary depending on the assay setup: (A) first addition of 
compound (B) first addition of protein (C) compound and protein has been pre-incubated. 
In the substrate degradation assay a mass change on the sensor surface is for example 
caused by an added protease digesting the protein immobilized on the sensor surface. 
 Sensors 2012, 12  4315 
 
 
As previously stressed, OWG-based approaches are typically performed using plate-based systems 
and the sensor surface in each well is only used in a single binding experiment. This opens up for the 
development of more complex, more functional biochemical assays that are coupled to a mass change 
on the sensor surface on OWG platforms. A typical example for such an assay would be the proteolytic 
degradation of a protein substrate immobilised on the sensor surface by an added protease. A simple 
schematic outline of the three most common assay types that can be performed on optical biosensors in 
small molecule screening is shown in Figure 1. 
In order to assess the value of the ISA format for small-molecule screening using optical detection 
systems,  with  the  focus  on  novel  high-throughput  instruments  as  displayed  by  plate-based  OWG 
systems, we conducted a comparative study using human trypsin as a model system on the SRU BIND 
and Corning Epic platform. The aim was to be able to directly compare the outcome of a defined 
screening set for a DBA, an ISA, a proteolytic assay performed on an OWG platform and a classical 
trypsin enzymatic assay using a small peptide as substrate. To our best knowledge, dedicated reports of 
the comparison of different assay formats on optical biosensors for small-molecule screening activities 
have not been published, yet. 
The results from this practical example will guide us in discussing the usage and requirements of 
the ISA format in contrast to other assay formats as well as discussing some brief examples of its 
successful application in fragment screening.  
2. Experimental Section  
2.1. Assays 
2.1.1. Chromogenic Assay 
To a compound plate containing 0.25 µL per well of compound (10 mM) in DMSO a volume of  
40 µ L trypsin I (Polymun Scientific) diluted in assay buffer (0.1 M Tris-HCl, 1 mM CaCl2, 0.1% (v/v) 
Tween-20, pH 8) was added. The plate was shaken and left to stand for 10 min. A volume of 10 µL 
Bz-Val-Gly-Arg-pNA (Bachem) substrate in assay buffer was then added to the compound plate to 
give a final substrate concentration at the Km value of Bz-Val-Gly-Arg-pNA for trypsin I (360 µ M). 
The increase in absorbance was then measured at 405 nm for 20 min at RT. Slopes were used to 
determine the inhibitory effects of the compounds. The chromogenic assay had a Z’ of 0.82. 
2.1.2. Biosensor Assays 
Three different assay formats were run on biosensors integrated into microplates using the SRU 
Bind (SRU Biosystems) or the Epic platform (Corning): a DBA, an ISA and a substrate degradation 
assay with bovine serum albumin (BSA, Sigma). In addition a DBA with active site blocked trypsin I 
was also run to detect unspecific binders and used in combination with the DBA to trypsin I alone. The 
binding values to active site blocked trypsin were subtracted from the binding values to active trypsin I. 
Active site blocked trypsin I was obtained by treating trypsin I with the irreversibly binding substrate 
analog  FPR-CMK  (Sigma).  In  the  ISA,  biotinylated-FPR-CMK  (Haematologic  Technologies)  was 
immobilized to the biosensor plate as bait. The characteristics of the four resulting biosensor assays are 
summarized in Table 1. Sensors 2012, 12  4316 
 
 
For immobilization of trypsin I or active site blocked trypsin I, 5041 plates from Corning were used. 
They contain pre-activated chemistry based on polymeric maleic anhydride groups. Proteins are bound 
by covalent (amide) bond formation with NH2 groups. BSA for the degradation assay was adsorbed to 
unmodified titaniumoxide coated biosensors in the microplates. Biotinylated-FPR-CMK was bound to 
pre-made streptavidin coated plates (SA-1) from SRU Biosystems. 
Table  1.  A  summary  of  the  assay  conditions  of  the  assay  formats  on  the  microplate 
biosensors specifying microplates used, immobilization conditions and Z’ values of the 
resulting assays. 
Assay format  DBA  DBA 
Degradation 
Assay 
ISA 
Immobilised on 
biosensor 
Trypsin I  Trypsin I & active site 
blocked trypsin I 
BSA  Biotinylated-FPR-CMK 
Biosensor  5041  5041  TiO2  SA-1 
Platform  Epic  Epic  SRU BIND  SRU BIND 
Immobilization 
buffer 
20 mM Na-acetate 
pH 5 
20 mM Na-acetate  
pH 5 
20 mM Hepes 
pH 8 
20 mM Hepes  
pH 7 
Immobilization 
concentration 
100 µ g/mL 
 
100 µ g/mL 
 
50 µ g/mL 
 
3 µ M 
Time of 
immobilization 
Overnight  Overnight  Overnight  30 min 
Trypsin I addition  -  -  1 µ g/mL  10 µ g/mL 
Z’  0.66  0.67  0.38  0.66 
2.2. Screening 
A test set of 323 compounds was selected from AstraZeneca’s screening database on the basis of 
previous  determined  IC50  values  available  for human  trypsin  I.  Further  criteria  for  selection  were  
Mw < 500 Da, LogD < 5, solubility > 10 µ M and finally a visual inspection of the compound structures 
by a medicinal chemist. The compounds were then divided into three subsets (Table 2), depending on 
their previously found activity. 
Table 2. Subsets of the test set. The selected compounds were divided into three different 
subsets depending on their previously found activity as outlined under description. 
Subset  Number of Compounds  Description 
Actives  171  Active compounds based on AstraZeneca data from previous 
trypsin assays. IC50 of less than 10 µ M. 
Non-actives  96  Compounds that showed no activity in the previous trypsin assays. 
Frequent 
hitters 
56  Compounds that have been tested in at least 40 assays and that 
have appeared as active in at least 60% of these. 
The set was run three times independently in each assay at a single concentration of 50 µM. A 
difference of at least 6 ×  SD from the background control in at least two of the three assay occasions 
was  used  as  criterion  to  define  a  hit  (=Active  A).  100%  effect  was  defined  by  an  AstraZeneca Sensors 2012, 12  4317 
 
 
developed trypsin inhibitor and used to define unspecific binding of compounds in the direct binding 
assays. All binding signal in the direct binding assays were corrected for the MW of the compound and 
the immobilization of trypsin in the respective well. 
3. Results and Discussion 
Proteases are a common drug target. Human trypsin I was chosen as model protein to test and 
compare  optical  biosensor  based  assay  formats  for  protease  inhibitor  discovery:  DBA,  ISA  and 
substrate degradation assay (see material and methods for details as well as Figure 1). The results from 
these were compared to those generated with a chromogenic enzymatic assay based on cleavage of a 
small  peptide.  The  different  assay  formats  were  first  compared  to  the  chromogenic  assay  by  the 
determination of the Kd or IC50 values for a selection of small molecules and protein inhibitors. The 
results are shown in Figure 2. 
Figure 2. Comparison of the chromogenic assay with the optical biosensor based assay 
formats  for  a  selection  of  small  molecule  and  protein  inhibitors.  IC50  values  for  the 
chromogenic assay are in µ M, for the DBA in (A) and (B) Kd values are given in µ M, for 
the substrate degradation assay (C) and the ISA (D), IC50 values are given in µ M. The solid 
lines show a 1:1 correlation. 
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It seems that the protein protease inhibitor SBTI and the small molecule compound nafamostat are 
outliers  in  the  DBA  assay  formats  by  ranking,  whereas  the  small  molecules  in  general  seem  to 
correlate well to the chromogenic assay (Figure 2). From the determination of Kd and IC50 values it 
was seen that the different assay formats differed in sensitivity, e.g., the ISA being less sensitive than 
the substrate degradation assay. However, this is in line with the higher amount of trypsin I used in this 
assay format (Table 1).  
We then compared the different assay formats with a larger set of compounds at one concentration 
as one would typically carry out in a primary screening effort to find new hits. However we composed 
a test set to incorporate a sufficiently high number of active compounds (desired hits) as well as  
non-actives and frequently hitting compounds based on previous screening experience with trypsin in 
our company. The results from this comparison are shown in Table 3. The substrate degradation and 
the ISA delivered results showing a good correlation to the chromogenic enzymatic assay. The DBA 
however  showed  a  considerable  different  outcome  for  the  test  set.  The  DBA  delivered  many 
compounds of the Non-active and Frequent hitters subset as hits (Table 3). The number of these false 
positives could be decreased by using active site blocked trypsin as control. However as a normal 
screening set in contrast to our selected test set is composed of mainly Non-actives; a 24% hit rate is 
still way too high. The DBA assay would therefore in reality deliver an overhelming number of false 
positives when compared to the ISA or degradation assay. This rate could be even higher, if no caution 
is taken to sort out unspecific binding compounds in the DBA setup. As it can be seen in Table 3, a 
main  reason  for  exclusion  as  real  hit  (N)  is  detection  of  unspecific  binding.  Surprisingly  also  a 
substantial number of compounds expected to be found as hits (as originating from the Actives subset) 
in the DBA showed unspecific binding, raising questions about their mechanism of action in the other 
assay setups. 
 
Table 3. Summary of the screening results for all assays. The results for the test set subsets 
are reported in % of the total. For the DBA, compounds showing unspecific binding (either 
high values compared to the expected maximum binding signal or similar binding to both 
trypsin I & active site blocked trypsin I) were classified as not being hits (N) and their % of 
the total is given in brackets. Hits are reported as A. 
Assays 
Subsets 
Actives  Non-Actives  Frequent Hitters 
  N  A  N  A  N  A 
Chromogenic assay  15  85  100  0  98  2 
DBA (Trypsin I)  56 (50)  44  55 (14)  45  72 (55)  28 
DBA (Trypsin I–active site 
blocked Trypsin I) 
58 (47)  42  75 (25)  24  89 (71)  11 
ISA  27  73  99  1  93  7 
Degradation assay  42  58  100  0  98  2 
These reflections promote the concept that  if microplate-based biosensors should be used in a 
primary screening setting, ISA or a substrate degradation assay should be first considered. Additionally, 
in these assays, the target protein is in solution in contrast to the DBA, where the protein is randomly 
immobilised to a surface at very high local density. This is in line to minimize the number of false Sensors 2012, 12  4319 
 
 
positive hits to be obtained in total. However, it must kept in mind that in the ISA and degradation 
assay format also additional methods are required to then filter out compound hits with an undesired 
mode of action (unwanted positives), e.g., unspecific binding or aggregating compounds. But again, 
considering total numbers, testing a small number of active hits delivered by an ISA or degradation 
assay with an orthogonal assay format for unwanted mode of action is more efficient than sorting out 
false positives from an overhelming number of hits as the DBA would deliver. 
 
Figure 3. OWG ISA screening results on two targets with different ligandability. Activity 
is  reported  as  %  Binding,  i.e.,  the  binding  of  the  target  protein  to  the  TDC-modified 
biosensor in presence of compound in relation to the controls containing only target protein. 
Non-actives are depicted in blue, Actives (as defined by a cut-off value) are depicted in red 
and Actives with positive NMR-binding results are depicted in green. Compounds that 
interfere  with  the  readout  due  to  aggregation  or  solubility  issues  are  depicted in  grey.  
(A) Shown is the fragment screening result for the target possessing high ligandability;  
(B) Shown is the fragment screening result for the target possessing low ligandability.  
 
The results obtained with trypsin as a model system indicate a good quality performance of the ISA 
format using plate-based OWG systems for small-molecule screening, in particular considering the 
ability to identify true binders as well as the low rate for false positive binders. In order to further 
evaluate  the  usefulness  of  this  assay  format  for  fragment  screening  utilizing  OWG  platforms,  we 
conducted a fragment screening campaign on an internal drug target with high ligandability (i.e., high 
probability  of  finding  small  molecule  inhibitors,  see  [23])  as  well  as  a  drug  target  with  low 
ligandability, in this case a protein-protein interaction (PPI). In order to validate the output from both 
screens we applied biomolecular NMR techniques, which are seen as a golden standard due to their 
superior detection sensitivity [1]. A set consisting of about 3,000 fragments was screened against the 
target  displaying  high  ligandability  using  the  ISA  format  on  the  SRU  BIND  system  utilizing  a 
specifically  designed  TDC  (see  Figure  3(A)).  The  screen  was  performed  at  100  M  compound 
concentration and returned 395 fragment hits (=13.2% hit rate) thus demonstrating a hit rate in line for Sensors 2012, 12  4320 
 
 
a  drug  target  with  high  ligandability.  From  the  initial  hit  set,  16  fragments  presenting  interesting 
chemotypes have been selected for further analysis employing NMR spectroscopy, and all 16 fragment 
hits  could  be  verified  as  competitive  molecules  binding  to  the  drug  target  indicating  a  very  high 
verification rate. 
The PPI target was screened in a parallel fashion by means of NMR as well as applying the OWG 
ISA format and was challenged with a set of about 800 fragments at 60 μM and 100 μM concentration 
respectively. Both the NMR screen as well as the OWG ISA returned four fragment hits (=0.5% hit 
rate) thus delivering a hit rate in line with expectations (see Figure 3(B)). Interestingly, one fragment 
could be identified in both approaches that also displayed the highest affinity. The other three NMR hits 
have been outside the range of detection for the ISA due to the incompatibility of their mM-affinity with 
the selected screening concentration of 100 μM. The other three fragments hits from the ISA are likely 
binding to the TDC and are thus displaying false positive hits, albeit at a very low rate.  
The successful application of the ISA method in real screening projects indicate a great potential of 
this  approach  for  small-molecule  screening  using  biosensors  in  terms  of  matching  the  needs  for  
high-throughput  screening  with  good  assay  sensitivity  and  robustness,  but  it  has  obviously  some 
shortcomings that need to be considered as well. A key element of the ISA is the availability of a 
suitable TDC–typically such molecules are not readily available and need to be specifically designed 
to  match  available  immobilisation  chemistries  as  well  as  to  exhibit  still  good  affinity  (typically  
sub-μM) to the target protein once immobilised. Some knowledge about the 3-dimensional structure of 
the target protein in conjunction with available substrates, ligands or compounds can be of tremendous 
help for the rational design of such tool compounds. For instance, the choice for the optimal position 
and length of the chemical linker that is used for tethering onto the biosensor can be greatly facilitated 
by structural information. The opportunity for docking of such molecules allows making informed 
judgements on the potential effects of the linker for the binding mode of the tool compound. Another 
interesting aspect is the possibility to use the TDC for the screening of other proteins within the same 
protein family, thus leading to the build-up of a target-family specific toolbox that is readily available 
for the screening of novel targets within the same protein family.  
As opposed to the DBA, the ISA will only give information about compounds that are in direct 
kinetic competition with the TDC or alter the affinity to the TDC by binding to an orthosteric site. 
Thus, the assay format will not help to identify compounds that bind to other potential binding sites, 
but will instead deliver direct information about the binding site specificity and location. As such, the 
assay can serve as a standard secondary screening setup in situations where different modes of binding 
need  to  be  considered  and  the  primary  screening  results  needs  to  be  scrutinised  for  competitive 
compounds. Comparing with the information obtained from fluidic-based technologies like SPR it is 
also worth to make the observation, that the information content tends to be larger due to the availability 
of kinetic binding information. This kind of information can obviously not be accessed from OWG 
platforms due to its plate-based nature making use of equilibrium binding data. Interestingly, the ISA 
format if used in the mode of adding a compound to an already equilibrated solution containing the 
target protein, can theoretically provide access to kinetic data as this information is actually contained 
in the decay profile that is typically seen when displacing the protein from the biosensor. A related 
approach has been described using fluorescently-labelled probes indicating a good feasibility to extract 
that information from time-resolved binding data from ISA experiments [24].  Sensors 2012, 12  4321 
 
 
The utilization of biological reagents and consumables during larger screening campaigns is in fact 
a  key  factor  influencing  cost  efficiency  and  can  actually  set  limits  for  the  screening  of  larger 
compounds libraries. The current experience with performing biochemical assays on OWG platforms 
in a DBA format is such that approximately 0.5–1 mg of target protein is required for immobilisation 
using a 384-well plate. As those plates are typically not regenerated after screening it is apparent that it 
will be impractical to screen a full HTS deck which typically comprises between 1–2 million compounds. 
Using the ISA format instead furnishes the opportunity to control the amount of target protein used for 
screening as this is very much determined by the affinity of the TDC. Furthermore the plates can be 
easily  regenerated  during  the  screening  campaign,  as  most  TDCs  are  compatible  with  applying 
relatively harsh conditions during regeneration, and can thus be recycled in the screening process. 
4. Conclusions/Outlook  
The recent introduction of microplate-based OWG platforms triggered us to assess the impact of an 
assay format that has been intensively used particular during the period after the launch of the first 
commercial SPR platform in 1990, on the success for small-molecule screening—the inhibition in 
solution assay (ISA). In summary, the above outlined experiences with ISA on OWG platforms point 
towards distinct advantages of this assay format for fragment screening as well as orthogonal screening 
for hit validation, where higher throughput screening capacity is required.  
In addition, we believe, the potential to use more functional biochemical assays on microplate-based 
OWG platforms, as exemplified here by the substrate degradation assay, has not yet been appreciated 
and exploited fully. Currently we are investigating further functional assays, e.g., buffer clot lysis 
assays to study coagulation factors, on OWG platforms, thus trying to reduce the gap between in vitro 
and in vivo assays leading to the identification of biologically relevant molecules.  
Acknowledgments 
We  would like to thank  Florian Raubacher and Tomas Fex  for the selection  of the test set of 
compounds for comparison of the human trypsin I assays. Furthermore we would like to thank Fredrik 
Edfeldt and Tomas Åkerud for the provision of the NMR data to allow for the comparison with the 
OWG ISA results. 
References  
1.  Holdgate, G.A.; Anderson, M.; Edfeldt, F.; Geschwindner, S. Affinity-based, biophysical methods 
to detect and analyze ligand binding to recombinant proteins: Matching high information content 
with high throughput. J. Struct. Biol. 2010, 172, 142–157. 
2.  Ladbury, J.E.; Klebe, G.; Freire, E. Adding calorimetric data to decision making in lead discovery: 
A hot tip. Nat. Rev. Drug Discov. 2010, 9, 23–27. 
3.  Holdgate,  G.A.;  Gill,  A.L.  Kinetic  efficiency:  The  missing  metric  for  enhancing  compound 
quality? Drug Discov. Today 2011, 16, 910–913. 
4.  Swinney, D.C. The role of binding kinetics in therapeutically useful drug action. Curr. Opin. 
Drug Discov. Devel. 2009, 12, 31–39. Sensors 2012, 12  4322 
 
 
5.  Huber,  W.  A  new  strategy  for  improved  secondary  screening  and  lead  optimization  using  
high-resolution SPR characterization of compound-target interactions. J. Mol. Recog. 2005, 18, 
273–281. 
6.  Danielson, U.H. Fragment library screening and lead characterization using SPR biosensors. Curr. 
Top. Med. Chem. 2009, 9, 1725–1735. 
7.  Giannetti, A.M. From experimental design to validated hits a comprehensive walk-through of 
fragment lead identification using surface plasmon resonance. Methods Enzymol. 2011, 493, 169–218. 
8.  Fang, Y.; Ferrie, A.M.; Fontaine, N.H.; Mauro, J.; Balakrishnan, J. Resonant waveguide grating 
biosensor for living cell sensing. Biophys. J. 2006, 91, 1925–1940. 
9.  Cunningham, B.T.; Li, P.; Schulz, S.; Lin, B.; Baird, C.; Gerstenmaier, J.; Genick, C.; Wang, F.; 
Fine, E.; Laing, L. Label-free assays on the BIND system. J. Biomol. Screen. 2004, 9, 481–490. 
10.  Dodgson,  K.;  Gedge,  L.;  Murray,  D.C.;  Coldwell,  M.  A  100K  well  screen  for  a  muscarinic 
receptor using the epic label-free system—A reflection on the benefits of the label-free approach 
to screening seven-transmembrane receptors. J. Recept. Signal Transduct. Res. 2009, 29, 163–172. 
11.  O’Shannessy, D.J.; Brigham-Burke, M.; Peck, K. Immobilization chemistries suitable for use in 
the BIAcore surface plasmon resonance detector. Anal. Biochem. 1992, 205, 132–136. 
12.  Congreve,  M.;  Rich,  R.L.;  Myszka,  D.G.;  Figaroa,  F.;  Siegal,  G.;  Marshall,  F.H.  Fragment 
screening of stabilized G-protein-coupled receptors using biophysical methods. Methods Enzymol. 
2011, 493, 115–136. 
13.  Rich,  R.L.;  Errey,  J.;  Marshall,  F.;  Myszka,  D.G.  Biacore  analysis with  stabilized  G-protein-
coupled receptors. Anal. Biochem. 2011, 409, 267–272. 
14.  Giannetti,  A.M.;  Koch,  B.D.;  Browner,  M.F.  Surface  plasmon  resonance  based  assay  for  the 
detection and characterization of promiscuous inhibitors. J. Med. Chem. 2008, 51, 574–580. 
15.  Dalvit, C. NMR methods in fragment screening: Theory and a comparison with other biophysical 
techniques. Drug Discov. Today 2009, 14, 1051–1057. 
16.  Hamalainen, M.D.; Zhukov, A.; Ivarsson, M.; Fex, T.; Gottfries, J.; Karlsson, R.; Bjorsne, M. 
Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of 
protein panels. J. Biomol. Screen. 2008, 13, 202–209. 
17.  Nordstrom,  H.;  Gossas,  T.;  Hamalainen,  M.;  Kallblad,  P.;  Nystrom,  S.;  Wallberg,  H.;  
Danielson, U.H. Identification of MMP-12 inhibitors by using biosensor-based screening of a 
fragment library. J. Med. Chem. 2008, 51, 3449–3459. 
18.  Karlsson, R. Real-time competitive kinetic analysis of interactions between low-molecular-weight 
ligands in solution and surface-immobilized receptors. Anal. Biochem. 1994, 221, 142–151. 
19.  Retra,  K.;  Geitmann,  M.;  Kool,  J.;  Smit,  A.B.;  de  Esch,  I.J.P.;  Danielson,  U.H.;  Irth,  H. 
Development of surface plasmon resonance biosensor assays for primary and secondary screening 
of acetylcholine binding protein ligands. Anal. Biochem. 2010, 407, 58–64. 
20.  Fong, C.C.; Lai, W.P.; Leung, Y.C.; Lo, S.C.; Wong, M.S.; Yang, M. Study of substrate-enzyme 
interaction between immobilized pyridoxamine and recombinant porcine pyridoxal kinase using 
surface plasmon resonance biosensor. Biochim. Biophys. Acta 2002, 1596, 95–107. 
21.  Cannon, M.J.; Myszka, D.G.; Bagnato, J.D.; Alpers, D.H.; West, F.G.; Grissom, C.B. Equilibrium 
and kinetic analyses of the interactions between vitamin B(12) binding proteins and cobalamins 
by surface plasmon resonance. Anal. Biochem. 2002, 305, 1–9. Sensors 2012, 12  4323 
 
 
22.  Geschwindner, S.; Olsson, L.L.; Albert, J.S.; Deinum, J.; Edwards, P.D.; de Beer, T.; Folmer, R.H. 
Discovery  of  a  novel  warhead  against  beta-secretase  through  fragment-based lead  generation.  
J. Med. Chem. 2007, 50, 5903–5911. 
23.  Edfeldt,  F.N.;  Folmer,  R.H.;  Breeze,  A.L.  Fragment  screening  to  predict  druggability 
(Ligandability) and lead discovery success. Drug Discov. Today 2011, 16, 284–287. 
24.  Neumann,  L.;  von  Kö nig,  K.;  Ullmann,  D.  HTS  reporter  displacement  assay  for  fragment 
screening  and  fragment  evolution  toward  leads  with  optimized  binding  kinetics,  binding 
selectivity, and thermodynamic signature. In Methods in Enzymology; Academic Press Inc.: San 
Diego, CA, USA, 2011; Chapter twelve, pp. 299–320.  
©  2012  by  the authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is  an  open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 